{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:20:02Z","timestamp":1793125202624,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clinthera.2013.06.019","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T15:13:54Z","timestamp":1375974834000},"page":"1082-1098","source":"Crossref","is-referenced-by-count":165,"title":["New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"nct00927459","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01082562","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01350960","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01437059","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01507831","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01516879","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01588496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01617655","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01623115","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01624142","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01644175","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01644188","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01663402","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01709513","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01763827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01763866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01763905","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01763918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01764633","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amirhossein","family":"Sahebkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.06.019_bib1","first-page":"S36","article-title":"Acute coronary syndromes: morbidity, mortality, and pharmaco-economic burden","volume":"15","author":"Kolansky","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2013.06.019_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2012.07.064","article-title":"Pathogenesis of acute coronary syndromes","volume":"61","author":"Crea","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib4","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.06.019_bib5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.06.019_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.019_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.amjmed.2005.11.015","article-title":"Contemporary management of dyslipidemia in high-risk patients: targets still not met","volume":"119","author":"Yan","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.06.019_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","volume":"59","author":"Mora","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib12","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib13","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib14","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib15","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic \u03b4\u03b4-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2013.06.019_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib21","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib22","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib23","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: master regulators of lipid homeostasis","volume":"86","author":"Eberl\u00e9","year":"2004","journal-title":"Biochimie"},{"key":"10.1016\/j.clinthera.2013.06.019_bib25","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes","volume":"582","author":"Langhi","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clinthera.2013.06.019_bib27","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin\/kexin type 9","volume":"283","author":"Kourimate","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib28","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and posttranslational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib29","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2013.06.019_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib31","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.12.043","article-title":"Plasma PCSK9 levels and clinical outcomes in the TNT, (Treating to New Targets) trial: a nested case-control study","volume":"59","author":"Huijgen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib34","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib35","first-page":"49394","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non additive fashion in diabetic patients","volume":"212","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib37","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1194\/jlr.M500526-JLR200","article-title":"A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity","volume":"47","author":"Schmidt","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pharmthera.2012.03.005","article-title":"Novel therapeutic agents for lowering low density lipoprotein cholesterol","volume":"135","author":"Joy","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.06.019_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11886-012-0345-z","article-title":"PCSK9 Inhibitors: potential in cardiovascular therapeutics","volume":"15","author":"Do","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clinthera.2013.06.019_bib43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11883-010-0099-2","article-title":"PCSK9 as a therapeutic target in atherosclerosis","volume":"12","author":"Marian","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2013.06.019_bib44","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib46","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib48","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib49","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib50","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib51","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.019_bib52","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.06.019_bib53","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib54","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.06.019_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.06.019_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","article-title":"Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe","volume":"48","author":"Yu","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2013.06.019_bib59","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib60","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","article-title":"Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein","volume":"286","author":"Du","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/protein\/gzq097","article-title":"Adnectins: engineered target-binding protein therapeutics","volume":"24","author":"Lipovsek","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.clinthera.2013.06.019_bib62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib63","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.06.019_bib64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2013.06.019_bib65","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2013.06.019_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib67","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1345\/aph.1K065","article-title":"ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?","volume":"41","author":"Ito","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2013.06.019_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-2275(20)32065-4","article-title":"Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions","volume":"41","author":"Packard","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib69","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0022-2275(20)38425-X","article-title":"Plasma very low density lipoproteins contain a single molecule of apolipoprotein B","volume":"29","author":"Elovson","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.nutr.19.1.141","article-title":"The mammalian low-density lipoprotein receptor family","volume":"19","author":"Hussain","year":"1999","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.clinthera.2013.06.019_bib71","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.amjcard.2005.10.060","article-title":"Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men","volume":"97","author":"St-Pierre","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib72","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.ATV.0000255580.73689.8e","article-title":"Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study","volume":"27","author":"Benn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib73","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1194\/jlr.M700213-JLR200","article-title":"Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese","volume":"48","author":"Chien","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib74","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.06.019_bib75","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2174\/138161211795428830","article-title":"Antisense oligonucleotides for the treatment of dyslipidemia","volume":"17","author":"Gouni-Berthold","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2013.06.019_bib76","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2013.06.019_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/clp.10.47","article-title":"Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen","volume":"5","author":"Thomas","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib78","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies. Improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib79","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.019_bib80","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib81","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib83","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib84","first-page":"S898","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease","volume":"31","author":"Stein","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.06.019_bib85","doi-asserted-by":"crossref","first-page":"E492","DOI":"10.1016\/S0735-1097(11)60492-0","article-title":"Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia","volume":"57","author":"Tardif","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib86","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32","author":"Akdim","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.06.019_bib87","doi-asserted-by":"crossref","first-page":"49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.06.019_bib88","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.019_bib89","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2005.06.018","article-title":"Hepatic steatosis and insulin resistance: does etiology make a difference?","volume":"44","author":"Lonardo","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib90","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","author":"Tarugi","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib91","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1016\/S0021-9258(18)90593-4","article-title":"A triglyceride and cholesteryl ester transfer protein associated with liver microsomes","volume":"259","author":"Wetterau","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.06.019_bib92","doi-asserted-by":"crossref","unstructured":"Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 200;44:22\u201332.","DOI":"10.1194\/jlr.R200014-JLR200"},{"key":"10.1016\/j.clinthera.2013.06.019_bib93","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MOL.0b013e328312707c","article-title":"New approaches to target microsomal triglyceride transfer protein","volume":"19","author":"Hussain","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2013.06.019_bib95","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jama.1993.03510070087042","article-title":"Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease","volume":"270","author":"Rader","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.06.019_bib96","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.282.5389.751","article-title":"An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits","volume":"282","author":"Wetterau","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2013.06.019_bib97","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1440-1681.2011.05513.x","article-title":"Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats","volume":"38","author":"Dhote","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib98","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.06.019_bib99","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2013.06.019_bib100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.019_bib101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(01)01419-4","article-title":"MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion","volume":"431","author":"Shiomi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1248\/bpb.28.247","article-title":"Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation","volume":"28","author":"Ueshima","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2013.06.019_bib103","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans","volume":"44","author":"Chandler","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib104","unstructured":"Dunbar RL, Bloedon LT, Gadi R, et al. Impact of high doses of the MTP-inhibitor, AEGR-733, on the single dose pharmacokinetics of atorvastatin and rosuvastatin. 2009. http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/ISA_2009_-_PK_high_dose_lomitapide_with_statin.pdf. Accessed April 28, 2013."},{"key":"10.1016\/j.clinthera.2013.06.019_bib105","unstructured":"Duffy D, Bloedon LT, Dunbar RL, et al. Impact of the MTP Inhibitor AEGR-733 on Pharmacokinetics of Statins. 2007. http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/DALM_2007-_effects_of_lomitapide_on_PK_with_statins.pdf. Accessed April 28, 2013."},{"key":"10.1016\/j.clinthera.2013.06.019_bib106","unstructured":"Dunbar RL, Bloedon LT, Duffy D, et al. Impact of the MTP Inhibitor AEGR-733 on pharmacokinetics of fenofibrate. 2007. http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/DALM_2007_-_effects_of_lomitapide_on_PK_with_fenofibrate.pdf. Accessed April 28, 2013."},{"key":"10.1016\/j.clinthera.2013.06.019_bib107","unstructured":"Dunbar RL, Bloedon LT, Gadi R, et al. Impact of High Doses of the MTP-Inhibitor Lomitapide (AEGR-733) on the Single-Dose Pharmacokinetics of Extended-Release Niacin. 2009. http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/ISA_2009_-_PK_high_dose_lomitapide_with_Niacin.pdf. Accessed April 28, 2013."},{"key":"10.1016\/j.clinthera.2013.06.019_bib108","unstructured":"Webster LA. Surface Logix achieves objectives with SLx-4090 in phase 2a clinical trial. 2008. http:\/\/www.drugs.com\/clinical_trials\/surface-logix-achieves-objectives-slx-4090-phase-2a-clinical-trial-3277.html. Accessed April 28, 2013."},{"key":"10.1016\/j.clinthera.2013.06.019_bib109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2261-5-30","article-title":"JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs","volume":"5","author":"Aggarwal","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2013.06.019_bib110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.110.177527","article-title":"A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile","volume":"337","author":"Kim","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.06.019_bib111","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1124\/jpet.110.173807","article-title":"Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4\u2032-trifluoromethylbiphenyl-2-carbonyl) amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein","volume":"336","author":"Mera","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.06.019_bib112","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.clinthera.2013.06.019_bib113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2011.02.012","article-title":"Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study","volume":"217","author":"Noguchi","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib114","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels","volume":"51","author":"Troutt","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.019_bib115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2013.06.019_bib116","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/euhj.1999.1995","article-title":"Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)","volume":"21","author":"Collinson","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.06.019_bib117","first-page":"S430","article-title":"Burden of disease: medical and economic impact of acute coronary syndromes","volume":"12","author":"Turpie","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2013.06.019_bib118","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2013.06.019_bib119","first-page":"109","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"15","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.019_bib120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.103.2.276","article-title":"An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro","volume":"103","author":"Aikawa","year":"2001","journal-title":"Circulation"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:28:33Z","timestamp":1646285313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813003470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0149291813003470"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.06.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}